FengHe Fund Management Pte. Ltd. Invests $44.25 Million in Merck & Co., Inc. $MRK

Key Points

• FengHe Fund Management bought a new Q4 position of 420,400 shares of Merck (MRK), valued at about $44.25 million, making MRK 2.5% of the fund's portfolio and its 16th-largest holding.
• Analyst sentiment is broadly positive with a MarketBeat consensus of "Moderate Buy" and an average target price of $128.47, backed by recent upgrades from Barclays (overweight), UBS (buy) and RBC (outperform).
• Insiders have been net sellers recently—320,176 shares sold (~$38.28 million) in the past 90 days—while institutional and hedge fund ownership remains high at about 76.07%.

FengHe Fund Management Pte. Ltd. bought a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 420,400 shares of the company's stock, valued at approximately $44,251,000. Merck & Co., Inc. makes up 2.5% of FengHe Fund Management Pte. Ltd.'s portfolio, making the stock its 16th biggest holding.

Several other institutional investors and hedge funds have also modified their holdings of the business. Cadence Bank boosted its holdings in shares of Merck & Co., Inc. by 0.8% in the 4th quarter. Cadence Bank now owns 39,068 shares of the company's stock worth $4,112,000 after acquiring an additional 309 shares in the last quarter. Vivid Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $218,000. Wealthfront Advisers LLC boosted its holdings in shares of Merck & Co., Inc. by 22.2% in the 4th quarter. Wealthfront Advisers LLC now owns 257,244 shares of the company's stock worth $27,078,000 after acquiring an additional 46,675 shares in the last quarter. Torren Management LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $161,000. Finally, Ares Financial Consulting LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $65,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Cleared a regulatory hurdle for the Terns Pharmaceuticals acquisition (Hart‑Scott Rodino waiting period expired); also highlighted CADENCE proof‑of‑concept data for Winrevair and European Commission approval of ENFLONSIA for infant RSV prevention — these advance revenue and pipeline catalysts. Merck Advances Terns Deal And Cardiovascular And RSV Growth Options
• Positive Sentiment: Analyst and media pieces point to Merck’s strong history of earnings beats and positioning for another upside surprise, supporting bullish near‑term expectations into the Q1 print. Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Featured as a "low risk, high growth" pick in recent coverage, reflecting investor interest in MRK’s diversified oncology and vaccine franchises that reduce single‑asset risk. Merck & Co. Inc. (MRK): One of the Best Low Risk High Growth Stocks to Buy Right Now
• Neutral Sentiment: Launched a public health education program (Playing with Heart) with baseball partners to raise LDL‑C awareness — positive for brand and prevention awareness but limited immediate financial impact. Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends...
• Neutral Sentiment: Macro/market coverage notes expansion in specialty markets (e.g., peripheral T‑cell lymphoma) where multiple competitors — including Merck’s Keytruda in some settings — could benefit from long‑term demand growth. Impact is gradual rather than immediate. Peripheral T-Cell Lymphoma Market to Witness Significant Expansion...
• Negative Sentiment: Some previews flag earnings risks: certain Zacks notes show divergent near‑term EPS assumptions (one preview cites a loss estimate for Q1), highlighting that accounting items, one‑offs or timing could pressure headline EPS despite revenue resilience. Investors face binary risk around the Q1 print. Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?

Analyst Ratings Changes

MRK has been the topic of several recent analyst reports. Barclays initiated coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. Citigroup boosted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a "neutral" rating in a report on Friday, March 20th. UBS Group boosted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Wolfe Research raised Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price on the stock in a report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $128.47.

Insider Activity

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the company's stock in a transaction on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares of the company's stock, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Caroline Litchfield sold 41,997 shares of the company's stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the transaction, the chief financial officer directly owned 90,192 shares in the company, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Stock Down 1.4%

NYSE:MRK opened at $110.28 on Tuesday. The stock's fifty day moving average price is $118.39 and its two-hundred day moving average price is $107.18. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The company has a market cap of $272.38 billion, a price-to-earnings ratio of 15.15, a P/E/G ratio of 2.27 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the business earned $1.72 EPS. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 4.89 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.